Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.52 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.51 |
| ▸ | CCR4 | P51679 | 9/20 | 0.50 |
| ▸ | CCR5 | P51681 | 1/20 | 0.47 |
| ▸ | CCKBR | P32239 | 1/20 | 0.46 |
| ▸ | PFKFB4 | Q16877 | 1/20 | 0.45 |
| ▸ | EDNRA | P25101 | 2/20 | 0.42 |
| ▸ | MMP8 | P22894 | 4/20 | 0.41 |
| ▸ | MMP3 | P08254 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6038793 | 0.85 | CCR4 (0.53) | PFKFB3CCR4CCR5EDNRA | |
| SCHEMBL6038701 | 0.82 | CCR4 (0.51) | PFKFB3CCR4CCR5EDNRA | |
| SCHEMBL6038706 | 0.82 | CCR4 (0.52) | PFKFB3CCR4CCR5CCKBRPFKFB4 | |
| SCHEMBL6038600 | 0.81 | CCR4 (0.60) | CCR4CCR5EDNRA | |
| SCHEMBL6038513 | 0.80 | CCR4 (0.50) | CCR4CCR5EDNRA | |
| SCHEMBL6039005 | 0.80 | CCR4 (0.73) | CCR4CCR5EDNRA | |
| SCHEMBL6038955 | 0.78 | CCR4 (0.50) | PFKFB3CCR4CCR5EDNRA | |
| SCHEMBL6039417 | 0.78 | CCR4 (0.54) | PFKFB3CCR4CCR5EDNRA | |
| SCHEMBL6038742 | 0.76 | CCR4 (0.71) | CCR4EDNRA | |
| SCHEMBL6038522 | 0.76 | CCR4 (0.69) | CCR4CCR5EDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1541563-A1 | CCR4 ANTAGONIST AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | CCR4, CCR1, CCR9 | GABRA1 1704/4885PFKFB3 3136/4885CCR4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.